echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Recently, the price of many commonly used drugs has been reduced, the gross profit of the drug retail industry has declined, and the status of pharmacies has risen

    Recently, the price of many commonly used drugs has been reduced, the gross profit of the drug retail industry has declined, and the status of pharmacies has risen

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Behind the suspension of the listing of Lianhua Qingwen in one province, many pharmacies often sell drugs in price reductions
    .
    Due to price reasons, Lianhua Qingwen in one province has suspended the listing of the Internet Maintained the winning bid price in all provinces in the country on time, and was suspended from the Internet

    .
    In this regard, Cyberblue-pharmacy manager immediately asked Yiling Pharmaceutical for verification

    .
    Relevant personnel of Yiling Pharmaceutical stated that Lianhua Qingwen Capsules (specification: 0.
    35g*24) were suspended from the Internet in Ningxia, mainly because the price stipulated by the platform was low, and the price of Lianhua Qingwen Capsules of this specification was high, which is a normal situation

    .
    Lianhua Qingwen, as the leading variety in pharmacies, has attracted much attention from the industry on price changes

    .
    Not long ago, the Hong Kong media "Toutiao Daily" reported that under the severe epidemic environment in Hong Kong, Lianhua Qingwen capsules were snapped up by the public, and the supply was in short supply.
    to 100 yuan, an increase of 257%

    .
    After the above news was released, industry media and readers have forwarded it

    .
    In contrast to the mainland market, the price fluctuation range of Lianhua Qingwen Capsules is generally not large

    .
    Taking Lianhua Qingwen Capsule (specification: 0.
    35g*24) as an example, the self-operated price of a well-known e-commerce platform is 13.
    9 yuan, and the price fluctuates in the range of 12-15 yuan

    .
    In addition to Lianhua Qingwen, the notice also announced a specific list of 19 drug price reductions, involving aspirin enteric-coated tablets and Shenshuining capsules commonly sold in pharmacies

    .
    It is understood that aspirin enteric-coated tablets have antipyretic, analgesic, anti-inflammatory, anti-rheumatic, anti-thrombotic and other effects, and are known as "universal medicine"; Shenshuining capsules are mainly used to invigorate qi and spleen, activate blood and remove blood stasis.
    , Tongfu venting turbidity

    .
    Recently, a number of commonly used drugs have been reduced in price, involving Liuwei Dihuang Pill.
    It was found that the notice of "drug price reduction" is not only the voice of Ningxia.
    Recently, many provinces across the country have issued relevant notices, and a large number of best-selling drugs will usher in price reductions.

    .
    On February 11, the Liaoning Provincial Centralized Purchasing Network for Medicines and Medical Consumables issued a notice that 33 medicines applied for an active price reduction, including Liuwei Dihuang Pills, Fuzi Lizhong Pills, and Zhibai Dihuang Pills.
    The net price is 12 yuan, and the manufacturer is Shaanxi Tangwang Tianyang Pharmaceutical

    .
    On February 7, Jiangsu issued a notice of drug price adjustment.
    34 drugs produced by 28 pharmaceutical companies ushered in price reductions.
    Among them, vitamin D2 soft capsules (0.
    125mg*10, produced by Nanjing Sea Whale) 48.
    5 yuan will be reduced to 41 yuan, hypoglycemic drugs Glipizide controlled-release tablets (5mg*14, produced by Nanjing Yiheng) dropped from 28.
    8 yuan to 28.
    5 yuan

    .
    It should be mentioned that although the above-mentioned platform price reduction notice is aimed at medical institutions, under the general trend of national drug price reduction driven by centralized procurement, the pharmacy market will inevitably be affected, and the pharmacy operating gross profit will inevitably decrease

    .
    Gross profit is declining, but status is rising.
    Reviewing the annual reports of listed chain pharmacies in recent years, it is found that the gross profit margins of drugs and non-drugs have declined to varying degrees, and the decline is generally within 10 percentage points

    .
    According to the Kaiyuan Securities Research Institute, the average gross profit margin of the pharmaceutical retail industry increased steadily from 2010 to 2016, but after 2016 it showed a fluctuating downward trend.
    The proportion of prescription drugs increased, which lowered the overall gross profit margin of the industry

    .
    It is worth noting that, despite the accelerated outflow of prescriptions, although the gross profit of pharmacies has decreased, the status of pharmacies has increased significantly, and has been sought after by capital.
    For example, the non-standard market represented by pharmacy terminals has been "cared for" by pharmaceutical companies

    .
    Take the first batch of centralized lipid-lowering drug "Rosuvastatin Calcium" as an example, after the original research manufacturer AstraZeneca was defeated, it launched into the pharmacy retail market

    .
    According to Zhongkang CMH data, in the first quarter of 2020, the sales of AstraZeneca's rosuvastatin calcium in the pharmacy market reached 410 million yuan, an increase of nearly 70% compared to the same period in 2019

    .
    Xie Zilong, chairman of the common people, said at the 2020 annual shareholders meeting that centralized procurement is more beneficial to the pharmacy chain industry, because pharmaceutical companies that have not entered the centralized procurement will be more inclined to choose to cooperate with pharmacies.
    This business brings benefits to the company.
    The gross profit margin will be relatively higher

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.